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Abstract
Melanomas, which originate from melanocytic cells, mainly develop in the skin but can 
also arise at other body sites. The disease accounts for approximately 90% of deaths 
related to cutaneous tumors with late stage metastatic melanoma having a very poor 
prognosis of 6–9 month median survival for untreated patients. Research in the last 
decades resulted in ground-breaking discoveries of melanoma genetics and biology. High 
frequency mutations in genes like BRAF, NRAS and KIT, which lead to hyper-activation 
of the MAPK signaling pathway, drive melanoma progression. Targeting the MAPK sig-
naling pathway has successfully been translated into effective therapies that significantly 
improve patient survival. Despite the unquestionable importance of such genetic events, 
the involvement of epigenetic alterations for melanoma development, and resistance to 
aforementioned therapies is becoming increasingly apparent. In this chapter, epigenetic 
alterations commonly found in melanoma are introduced, with a focus on histone and 
DNA modifications and their relevance for melanoma development, progression and 
therapy response. Detailed knowledge about this emerging aspect of melanoma research 
will help to understand the plastic nature of melanoma and set the foundation for novel 
treatment strategies that target aberrant gene regulation on genetic and epigenetic levels.
Keywords: biomarker, drug resistance, histone modifications, DNA methylation, 
melanoma, targeted therapy
1. Introduction
The grim prognosis for metastatic melanoma patients and the steadily increasing rates of 
melanoma incidents, that are projected to continuously rise within the next decades [1], rep-
resent a challenge for healthcare systems worldwide and highlight the importance of devel-
oping and optimizing prevention strategies, diagnostic approaches and treatment regimes. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
After many years of research with unsatisfying treatment options and poor clinical outcomes, 
last decade has seen major advances in the therapy of metastatic melanoma driven by the 
revolutionizing discoveries of driver mutations and immune escape mechanisms that con-
tribute to the aggressive nature of this disease. Drugs, developed to specifically exploit these 
mechanisms, administered either alone or in combination, have been shown to be clinically 
effective treatment strategies significantly increasing survival rates of patients [2–5]. Despite 
these recent ground-breaking advances in melanoma therapy, no currently available treat-
ment options are curative in the majority of responding patients nor do all patients with 
BRAFV600E mutations respond to targeted therapies. Melanoma and targeted inhibition of 
oncogenic BRAFV600E became the poster child of an exciting initial therapy success followed by 
long-term resistance, which has also been experienced with other promising novel treatment 
strategies like immune checkpoint inhibitors targeting CTLA-4 and PD-1. The benefit of these 
new therapies is limited by the emergence of resistance, ultimately leading to tumor relapse. 
While the importance of genetic alterations for the development of disease and therapy resis-
tance is unquestionable, it turns out that epigenetic remodeling is a fundamental feature of 
tumor development and adaption to therapy.
This chapter will briefly introduce the concept of epigenetics focusing on epigenetic altera-
tions, especially changes in histone and DNA modifications during melanoma development 
and the emergence of therapy resistance. Detailed investigations into these changes will 
greatly contribute to our understanding of the heterogeneous and adaptive nature of mela-
noma. A thorough perception of how epigenetic drivers are modulating the genetic landscape 
will be the foundation for the development of new treatment strategies beyond pathway and 
immune checkpoint inhibitors.
2. Epigenetic changes
It has long been recognized that chromatin contains information beyond the primary DNA 
sequence. This information that is stored “on top of” the genetic information is highly dynamic 
and influences gene expression patterns and phenotypes without altering the nucleotide 
sequence while maintaining heritability to somatic daughter cells and in some cases even 
offspring via the germline. Multiple epigenetic mechanisms have been identified including 
ATP-dependent chromatin remodeling, the non-coding RNAs and different histone variants 
[6]. Here, we focus on the two most well studied aspects of epigenetic gene regulation, DNA 
methylation and histone modifications.
2.1. DNA methylation
The most well studied form of epigenetic information is stored by direct covalent chemical 
modification of the DNA itself. Cytosine residues in CpG dinucleotides are methylated at 
the fifth position generating 5-methyl cytosine (5-mC) (Figure 1) without affecting Watson-
Crick base pairing and sequence information [7]. This modification is consistently found in 
most eukaryotic model systems [8]. Generally speaking, DNA methylation is associated with 
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transcriptional repression [9] and established by DNA methyltransferases namely DNMT1, 
DNMT3A and DNMT3B. While DNMT1 is responsible for the maintenance of DNA methyla-
tion, DNMT3A and DNMT3B catalyze the de novo synthesis of 5-mC [10]. Conversely, 5-mC 
can be removed either by replication-dependent dilution or active DNA de-methylation by 
ten-eleven translocation (TET) proteins. TET proteins are Fe(II)/α-ketoglutarate-dependent 
dioxygenases that catalyze the oxidation of 5mC to 5-hydroxymethylcytosine (5hmC) and 
further to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), which eventually is removed 
via base excision repair (BER) to restore un-methylated cytosine (Figure 1) [11]. Aberrant 
DNA methylation is a wide spread phenomenon in all cancers [12] suggesting an important 
role in malignant transformation.
Figure 1. Schematic representation of DNA methylation and histone acetylation/methylation. The basic structural 
unit of eukaryotic DNA is the nucleosome. A nucleosome includes 147 bp of DNA that is wrapped around a histone 
octamer consisting of two copies of each core histone protein H2A, H2B, H3 and H4. The N-terminal tails of the histones 
protrude from the core particle and are subject to posttranslational modifications. Lysine residues (K) of several histone 
tails can be either acetylated (Kac) by histone acetyltransferases (HAT) or mono-, di- or tri-methylated (Kme, Kme2 or 
Kme3) by histone methyltransferases (HMT). These modifications can be reversed by corresponding histone deacetylases 
(HDAc) or histone demethylases (HDM). Additionally, arginine residues (R) can be either mono- or di-methylated (Rme 
or Rme2), whereby di-methylation can be presented either symmetrically or asymmetrically. Cysteine residues (C) 
can be directly methylated by DNA methyltransferases (DNMT) resulting in 5-methylcytosine (5mC), which can be 
further processed as part of active DNA demethylation to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 
5-carboxylcytosine (5caC) by ten-eleven translocation (TET) proteins. DNA demethylation is then completed by thymine 
DNA glycosylase (TDG)-dependent base excision repair (BER).
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2.2. Histone modifications
Regulatory epigenetic information is also embedded in the basic structure of chroma-
tin and the nucleosome. The nucleosome core particle comprises 147 bp of DNA that is 
wrapped around an octamer of histone proteins consisting of two copies of H2A, H2B, 
H3 and H4 (Figure 1). Histones, especially the N-terminal tails, are subject to a multitude 
of posttranslational modifications including acetylation, methylation, phosphorylation, 
sumoylation, ubiquitylation or O-GlcNAcetylation with new modifications continuously 
identified [13]. The genome can be classified in transcriptionally active “open” euchromatin 
and transcriptionally inactive “closed” heterochromatin. Histone lysine acetylation affects 
this “open” and “closed” states by converting the charge of the affected residue at the his-
tone tail, which decreases the histone/DNA interactions, increases DNA accessibility and 
therefore facilitates transcription and replication [14]. Alternatively, histone modifications 
can act as binding motives for transcription factors and other histone-modifying enzymes. 
For example, bromodomains specifically recognize acetylated lysine residues and are an 
important part of many chromatin-associated proteins [14]. The second very prominently 
studied histone modification is methylation of lysine or arginine residues. In contrast to 
acetylation, methylation can be present in different forms. Lysine residues can be mono-, 
di- or tri-methylated, while arginine residues can be mono-methylated or symmetrically or 
asymmetrically di-methylated, neither of which affects the charge of the amino acid side 
chain (Figure 1) [15]. Instead, methylated histone residues are recognized by a plethora of 
protein domains including plant homeodomain (PHD) zinc fingers, chromodomains, Tudor 
domains or WD40 repeats [16]. While histone acetylation is generally associated with active 
transcription, histone methylation has more diverse functions depending on the location 
of the modification. For example, H3K4me3 or H3K36me3 are usually found in active gene 
promoters whereas H3K9me3 or H3K27me3 are linked to transcriptional repression [13]. 
Histone modifications are generally reversible and dysregulation of either ‘writers’ (e.g. 
histone acetyltransferase or histone methyltransferases) or ‘erasers’ (e.g. histone deacety-
lase or histone demethylases) are attributed to the pathogenesis of human diseases [17].
3. Epigenetics in melanoma initiation and development
High-throughput DNA sequencing enabled detailed investigations into the genetic makeup 
of cancer and revealed hundreds of genes that are frequently mutated in melanoma [18]. 
Among these, a set of driver mutations has been identified that allows melanocytes to pro-
liferate excessively, to overcome senescence and to divide indefinitely, resulting in their 
transformation into melanoma [19]. Despite the undeniable importance of genetic events, 
detailed knowledge of the molecular mechanisms of tumor initiation is still absent. This is 
due to the fact that such events, like epigenetic changes, are challenging to observe because 
models that represent individual stages of melanomagenesis are required. Nevertheless, the 
importance of epigenetic dysregulation in melanoma development becomes increasingly 
apparent, which is emphasized by the high frequency of mutations found in  epigenetic 
regulators [20].
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3.1. DNA methylation in melanoma development
One model used to investigate epigenetic alterations during melanoma development uti-
lizes sequential cycles of anchorage blockade to transform mouse melanocytes resulting 
in cell lines that show different degrees of aggressiveness and in vivo tumor growth poten-
tial, to mimic different stages of melanomagenesis [21]. Investigating DNA and histone 
modifications in this model showed substantial epigenetic changes as global DNA meth-
ylation was decreased while multiple histone modifications including H4K16ac, H3K4me3, 
H3K27me3 and H3K9me3 were increased [21]. These findings are consistent with data 
from melanoma cell lines showing global hypo-methylation compared to melanocytes 
[22–24] with 11 out of 14 types of repetitive DNA elements being hypo-methylated [22]. 
Considering that repetitive DNA sequences constitute more than 45% of the human genome 
[25], changes of their methylation patterns affect the readout of global DNA methylation 
the most. Demethylation of these repetitive DNA elements has been reported to negatively 
influence chromatin organization, increase genetic instability or result in gene deregulation, 
all of which can promote tumorigenesis [26–28]. Microarray analysis of 27 common benign 
nevi and 22 primary invasive melanomas that covered 1505 CpG sites of regulatory regions 
of 807 cancer-related genes identified 26 CpG sites, associated with 22 genes that showed 
significant methylation differences. Of these 26 CpG sites, 19 showed significant hypometh-
ylation with 7 hypermethylated [29].
While it appears that global DNA methylation levels are decreased during melanocyte trans-
formation, many gene-specific CpG islands are hypermethylated. Comparing 24 primary 
cutaneous melanomas and 5 benign nevi using the Infinium BeadChip technology covering 
27,578 CpG loci in the promoter regions of 14,495 genes identified 106 hypermethylated and 
44 hypomethylated CpG islands. Among the 106 hypermethylated genes, MAPK13, which 
encodes the p38 isoform, has been found to have tumor suppressive functions as retrovirus-
mediated overexpression of this gene displayed cytostatic effects and reduced melanoma 
growth in vitro [30]. Another interesting target gene that has been found to be regulated 
by DNA hypermethylation is the master regulator of pigmentation, MITF [31]. Lauss, et al. 
showed that hypermethylation of CpG islands belonging to MITF or MITF target genes cor-
related with decreased expression in metastatic melanoma tumors and melanoma cell lines. 
Melanoma cell lines that show intrinsically low MITF expression displayed CpG hypermeth-
ylation while cell lines that show high endogenous MITF levels were characterized by hypo-
methylation of these CpG islands. Accordingly, treatment with the DNA methyltransferase 
inhibitor 5′-Aza-2′-Deoxycytidine resulted in re-expression of MITF in MITF low cell lines. 
However, this re-expression was not sufficient to induce expression of the MITF target gene 
MLANA, suggesting that DNA methylation is involved but not sufficient to regulate MITF 
pathway activity in melanoma [31].
Differences in DNA methylation between melanocytes and melanoma can also be attributed 
to mutant BRAF, the most frequently mutated gene in melanoma [32]. Knockdown of BRAF 
in BRAF-mutant melanoma cell lines resulted in profound alterations of the methylation 
landscape with changes in gene expression affecting proliferation and invasion. Furthermore 
knockdown of BRAF significantly decreased DNMT1 and EZH2 expression suggesting that 
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BRAFV600E-mediated pathway activation has a profound influence on the epigenetic landscape 
[33]. Analyzing BRAFV600E and BRAFWT samples from The Cancer Genome Atlas (TCGA) 
revealed that BRAFV600E correlates with global DNA hypomethylation. Primary melanoma 
samples showed a significantly decreased expression of DNMT3A, which is mainly respon-
sible for de novo DNA methylation. Interestingly, DNMT3A expression was not found to be 
decreased in BRAF mutant BRAF wild type metastatic melanoma samples, suggesting that 
downregulation of this DNA methylatransferase is a transient event that might be impor-
tant for melanoma initiation but not for metastatic spread and maintenance of global DNA 
hypomethylation [34]. Furthermore, Fang, et al. showed that BRAFV600E drives DNA hyper-
methylation and gene silencing of specific target genes in a v-maf avian musculoaponeu-
rotic fibrosarcoma oncogene homolog G (MAFG) dependent manner in colorectal cancer 
and melanoma [35]. Specifically, MAFG is phosphorylated by the BRAF downstream kinase 
ERK1. This phosphorylation increases protein stability by reducing polyubiquitination and 
subsequent proteasomal degradation. MAFG then binds target gene promoters and recruits 
co-repressors including DNMT3B, ultimately resulting in DNA hypermethylation and gene 
silencing [35]. Unsupervised clustering of DNA methylation data from metastatic melanoma 
samples and TCGA melanoma samples identified three subgroups of melanoma tumors with 
differential methylation patterns [36]. These clusters did not correlate with either BRAF- or 
NRAS-mutation status nor primary tumor features like Breslow thickness or Clark’s level, 
suggesting that factors beyond BRAF regulate DNA methylation in melanoma. The hyper-
methylated cluster (MS1) was associated with cell proliferation while the cluster with the 
lowest methylation levels (MS3) was associated with immunity, indicating a fundamental role 
of DNA methylation on melanoma and the microenvironment [36].
3.2. Histone modifications during melanoma development
Remarkable insights into the importance of histone modifications for melanoma development 
have been revealed using a zebrafish model in which the human BRAFV600E gene is under the 
control of the mitfa-promoter crossed onto a p53 loss-of-function background. This model 
develops nevi that eventually progress into melanoma [37]. Like in most genetically engi-
neered animal models, only a small fraction of genetically identical melanocytes transform 
into melanoma, highlighting the importance of molecular events beyond genetic alterations 
to drive melanoma development. To address this problem and investigate melanoma initia-
tion in more detail, Kaufman, et al. developed a triple transgenic zebrafish model (p53/BRAF/
crestin:EGFP) in which a crestin/enhanced green fluorescent protein (crestin:EGFP) allows 
the visualization of neural crest stem/progenitor cells, the precursors of melanocytes [38]. 
Melanomas, which developed in these animals reestablish crestin:EGFP expression indicating 
that these cells reverse into a neural crest progenitor state. Knockout of sox10, a master regu-
lator of neural crest identified and regulated by acetylation of histone 3 lysine 27 (H3K27Ac), 
significantly delayed melanoma onset. H3K27Ac in super enhancers at the SOX10 locus was 
also found to be enriched in human melanoma cell lines indicating that epigenetic regulation 
of SOX10 expression is an important step of melanoma initiation [38].
Several histone-modifying enzymes have been shown to function aberrantly and contribute to 
melanoma progression. The H3K9me3-specific histone methyltransferase SET domain bifurcated 1 
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(SETDB1) is recurrently amplified within a region of chromosome 1 and shows a high expression 
in melanoma compared to nevi or normal skin [39]. Using the same zebrafish model as described 
above (mitfa-promoter crossed into a p53 loss-of-function background), Ceol, et al. identified that 
SETDB1 amplification accelerates melanoma onset and increased invasivness. This was found to 
be independent of SETDB1 enzyme activity. Instead SETDB1 is part of a multimeric H3K9 meth-
yltransferase complex including the H3K9me3 methyltransferase SUV39H1. Overexpression of 
SUV39H1 in the same zebrafish model also resulted in accelerated melanoma onset suggesting 
analogue functions of the entire H3K9 methyltransferase complex influencing melanoma devel-
opment, at least partially by abrogating oncogene-induced senescence [39].
Another deregulated histone-modifying enzyme during melanoma development is the 
H3K27me3-specific histone methyltransferase enhancer of zeste 2 polycomb repressive com-
plex 2 subunit (EZH2). EZH2 and H3K27me3 have been found to be elevated in aggressive 
melanoma cell lines and metastatic tumor samples. The expression of tumor suppressors 
RUNX3 and E-cadherin was found to be suppressed by EZH2 dependent H3K27me3 [40]. 
Accordingly, EZH2 is a major factor for melanoma initiation and progression. Knockout of 
EZH2 in a genetically engineered NRASQ61K melanoma mouse model reduced the number of 
melanomas and prevented metastasis formation [41]. Mechanistically, this was mediated by 
EZH2 target genes including deoxycytidine kinase (DCK), adenosylmethionine decarboxylase 
1 (AMD1) and WD repeat domain 19 (WDR19) which are suppressed in H3K27me3-dependent 
manner [41]. A possible explanation for EZH2 facilitating melanoma development could be by 
enabling senescence evasion. Knockdown of EZH2 in melanoma cells reestablished a senes-
cence phenotype partially by reactivating p21/CDKN1A transcription, which was found to be 
independent of H3K27me3. Instead, at the transcriptional start site of p21/CDKN1A, H3K14ac 
was increased as a result of decreased recruitment of histone deacetylase 1 (HDAC1), which 
correlated with transcriptional activation [42]. This is in line with reports that EZH2, as part 
of the Polycomb repressive complex 2 (PRC2), is able to recruit histone deacetylases, which 
shows functional synergy with H3K27me3 in mediating target gene silencing [43]. Later, it 
was found that the non-canonical NF-kB pathway regulates EZH2 expression by direct bind-
ing of NF-kB2 to the EZH2 promoter. Inhibition of NF-kB2 induced a senescence-like pheno-
type, which was reversible upon EZH2 re-expression [44]. Not suprisingly, pharmacological 
inhibition of EZH2 has been shown to impair melanoma growth in vitro and in vivo [41, 44, 45] 
and has emerged as a interesting target in multiple cancer types [46].
A more specific example how histone modifications promote melanoma progression is found 
in the case of the telomerase reverse transcriptase (TERT). Recently, activating TERT promoter 
mutations result in new transcription factor binding sites within the promoter, have been 
identified in up to 71% of all melanomas, which equals or even exceeds the frequency of BRAF 
and NRAS mutations, suggesting a key role for this genetic alteration in melanoma devel-
opment [47]. Interestingly, mutations in the TERT promoter frequently co-occur with BRAF 
mutations [48–50]. In fact it was found that MAPK pathway inhibition decreased H3K4me3 
and H3K9ac in the mutant TERT promoter region. This resulted in loss of RNA polymerase II 
(Pol II) recruitment and decreased TERT transcription. Mechanistically, ERK2 directly binds 
mutant TERT promoters and inhibits HDAC1 repressor complex recruitment, which results 
in active TERT transcription [51].
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A systematic overview of the epigenomic landscape of two phenotypically distinct melanocyte 
cell models that are characterized by low or high tumorigenicity showed distinct chromatin 
states associated with melanomagenesis. Specifically, chromatin state transitions character-
ized by loss of histone acetylation marks like H3K27Ac, H2BK5Ac and H4K5Ac and di-/tri-
methylation of H3K4 in regulatory domains associated with signaling pathways important for 
melanoma including phosphatidylinositol 3-kinase (PI3K), interferon (IFN) γ-, LKB1-, TRAIL- 
and platelet-derived growth factor (PDGF)-mediated signaling was observed, again empha-
sizing the link between epigenetic changes and melanoma development and progression [52].
Especially, loss of H3K4 methylation seems to be a key factor for melanoma growth and the 
highly problematic intratumor heterogeneity frequently observed in melanoma [53]. The 
histone 3 K4 demethylases jumonji/ARID1 (JARID1/KDM5B/PLU-1/RBP2-H1) defines a 
subpopulation of slow cycling melanoma cells, which is important for continuous growth 
of melanoma tumors. Interestingly, this subpopulation was found to be highly dynamic, as 
isolated KDM5B-positive and negative melanoma cells give rise to a heterogenous population 
consisting of both subpopulations [54] which highlights the variable nature of the epigenetic 
landscape in melanoma.
3.3. Epigenetic modifications as biomarkers and prognostic factors in melanoma
Because of the profound differences in DNA methylation patterns between melanocytic 
nevi and melanoma, several studies have investigated the suitability of DNA methylation 
as a predictive biomarker in melanoma. Unsupervised hierarchical clustering of 27 common 
benign nevi and 22 primary invasive melanomas resulted in separation of the two sample 
cohorts. Specifically, 22 genes were identified that significantly distinguished melanomas 
from nevi whereas 14 of these genes were validated in a separate set of 25 melanomas and 
29 nevi [29] suggesting that analysis of differential DNA methylation patterns could be used 
as melanoma biomarkers. Later on Gao, et al. investigated the methylation differences of 
common nevi, dysplastic nevi, primary melanomas and metastatic melanomas and estab-
lished a diagnostic algorithm based on promoter methylation patterns of CLDN11, CDH11, 
PPP1R3C which was able to distinguish dysplastic nevi from melanomas with a specific-
ity of 89% and sensitivity of 67% [55]. DNA methylation changes, however, are not lim-
ited to melanoma development (nevi versus primary melanoma) but are also apparent in 
melanoma progression (primary melanoma versus metastatic melanoma). DNA methylation 
profiling using Illumina Infinium Human Methylation 450 K Beadchips of 14 normal nevi, 
33 primary melanomas and 28 melanoma metastases identified gene promoters that were 
hypermethylated during melanoma development or melanoma progression [56]. Promoter 
methylation of several identified genes including HOXA9, MEOX2, RBP1, TFAP2B, TWIST1 
and AKT3 were shown to be suitable biomarkers to distinguish between nevi, primary and 
metastatic melanoma. AKT3 and TFAP2B protein expression was also confirmed as bio-
markers suitable for staining by immunohistochemistry. Furthermore, Wouters, et al. were 
able to correlate hypomethylation of MEOX2, OLIG3 and PON3 promoter hypomethyl-
ation with increased overall free survival [56]. Another major player in melanoma develop-
ment that has been shown to be regulated by DNA methylation is Phosphatase and Tensin 
Homolog (PTEN). PTEN inactivating mutations or deletions have been found in 12% of the 
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TCGA melanoma cohort [57]. However, loss of PTEN expression is a more frequent event 
as reduced expression has been observed in approximately 50% of stage IIIB/C melanomas 
with a complete loss in 20–25% of all samples which correlated with decreased overall sur-
vival [58]. Accordingly, PTEN promoter methylation was found in 60.7% in the TCGA mela-
noma cohort and was an independent predictor for impaired patient survival [59]. Besides 
gene-specific DNA methylation, hypomethylation of repetitive DNA elements has also been 
associated with patient survival. Two studies report contradicting findings. Sigalotti, et al. 
analyzed cell lines isolated from 42 stage IIIC patients and reported that hypomethylation 
of 2 out of 3 CpG sites within Long Interspersed Nucleotide Element-1 (LINE-1) sequences 
correlated with improved prognosis and 5 year overall survival [59]. In contrast, Ecsedi, et 
al. extracted genomic DNA from primary melanoma and found that hypomethylation of 6 
CpG sites associated within LINE-1 sequences in 46 primary melanomas correlated with 
decreased relapse-free survival of the corresponding patients and was also found to be asso-
ciated with increased metastatic capacity [60]. A possible explanation for these contradictory 
results could be fundamental differences in the way how samples were analyzed. Sigalotti, 
et al. isolated and cultured melanoma cells from primary tumor tissue which might have 
affected the DNA methylome leading to the observed differences.
Besides changes in DNA methylation (5-mC), genome wide loss of the DNA demethylation 
intermediate 5-hydroxymethylcytosine (5-hmC) has recently been found to be a hallmark 
of melanoma [61]. Specifically, it has been shown that 5-hmC levels are progressively lost 
in melanoma compared to benign nevi, which was accompanied by decreased expres-
sion of TET family members and IDH2. Re-establishing 5-hmC by overexpression of TET2 
reduced tumor growth and invasion suggesting an important function for 5-hmC in mela-
noma pathology. Accordingly, high levels of 5-hmC were found to negatively correlate with 
Breslow depth and predict better survival [61]. These findings were confirmed later on and 
suggest that 5-hmC analysis by immunohistochemistry could be a promising candidate as a 
prognostic biomarker in melanoma [62].
Presumed correlations between histone modifications and melanoma progression with prog-
nosis have not been investigated compared to DNA methylation. This is in part because of 
technical challenges eminent by direct assessment of histone modifications [63]. Martinez, et 
al. performed immunohistochemical analyses of 10 benign nevi, 25 primary cutaneous mela-
nomas without metastases, 19 primary cutaneous melanomas with metastases and 33 meta-
static melanomas using an antibody specifically detecting H3K79 trimethylation and H3T80 
phosphorylation (H3K79me3T80ph). They found a significant increase of H3K79me3T80ph 
in melanoma compared to nevi seemingly identifying a subset of primary melanomas with 
metastatic potential [64]. Another strategy to utilize histone modifications as biomarkers and 
prognostic factors that avoids the technical difficulties of direct assessment of histone modifi-
cations is to investigate the expression levels of histone-modifying enzymes. Along this line, it 
has been reported that the expression of the H3K27-specific histone methyltransferase EZH2 
is increased during melanoma progression. However, only metastatic melanomas showed 
a significant increase compared to nevi [65]. Accordingly, analyses of EZH2 expression of 
TCGA melanoma samples showed a significantly shorter survival of patients with high EZH2 
expression. Additionally, EZH2 high patients developed distant metastases faster, suggesting 
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a role for EZH2 in metastasis formation [41]. In contrast to EZH2, KDM5B has been found 
to be significantly downregulated during melanoma development. About 70% of the inves-
tigated nevi samples showed a KDM5B expression compared to 10 and 30% in primary and 
metastatic melanoma samples, respectively [66].
To our knowledge and despite the wealth of epigenetic changes that differentiate melanocytes 
and melanoma, no epigenetic biomarkers are used in the clinic to date.
4. Impact of epigenetic modifications on melanoma therapy
4.1. Acquired drug resistance, an obvious problem in melanoma therapy
Despite tremendous advances in developing innovative cancer therapies within the last few 
years, mechanisms for treatment failure are still not fully understood. Targeted inhibition 
of oncogenic BRAFV600E melanomas became the poster child of exciting initial therapeutic 
responses unfortunately followed by long-term resistance. Development of therapy resistance 
is the major obstacle for the successful use of targeted therapies, where almost all patients, 
who respond initially, are relapsing, irrespectively of single or combined inhibition of the 
MAPK pathway [67]. Furthermore, 15–20% of mutant BRAF tumors do not respond to tar-
geted therapy in the clinical setting [68], suggesting the presence of pre-existing resistance 
mechanisms. Resistance to MAPK pathway inhibition has been shown to involve emergence 
of genetic mutations in RAS or MEK, amplification of mutant BRAF or alternative BRAF splic-
ing [69, 70]. However, such genetic resistance mechanisms are absent in approximately 40% 
of patient samples, indicating the involvement of other mechanisms contributing to therapy 
failure [67]. Among these mechanisms, the upregulation of CRAF [71] or the SOX10-mediated 
activation of TGF-β that results in increased EGFR and PDGFRβ expression [72] that have 
been reported to mediate non-genetic resistance. Elevated EGFR and PDGFRβ levels have 
been shown to be reversible after discontinuing BRAF and MEK inhibitor treatment, while 
expression of EGFR or treatment with TGF-β resulted in a slow cycling drug-resistant pheno-
type [72]. This observation reflects findings by our group [73] and others [74, 75] of reversible 
multidrug-tolerant slow-cycling state following stressors like drug treatment. Beside failure 
of BRAF inhibition, a recent study found that dynamic and recurrent non-genomic alterations 
following chronic BRAF inhibitor treatment also affect tumor immunity possibly resulting in 
cross resistance to anti PD-1 therapy [76].
Even though immunotherapies like IL-2, adoptive T-cell transfer or antibodies that block 
CTLA-4 or PD-1 have shown long-term responses in some patients [77–80], many patients 
eventually relapse as melanoma cells escape immune surveillance. Genetic mechanisms like 
loss or mutation of specific antigens or parts of the major histocompatibility complexes that 
are involved in antigen presentation, have been attributed to immune evasion [81]. More 
recently, loss of function mutations in interferon-receptor signaling and in antigen presenta-
tion have been linked to resistance to PD-1 inhibition in three of four investigated patients 
[82]. Beside these genetic alterations that cause immunotherapy resistance, the expression 
of several melanoma antigens is linked to the dynamically regulated expression of NGFR 
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[83] or can be reversibly lost in response to inflammation [84]. Another study found a cor-
relation between a mesenchymal transcription signature, including WNT5A and ROR2, with 
resistance to anti-PD-1 therapy in metastatic melanoma [85] suggesting the involvement of 
epithelial-mesenchymal transition in immunotherapy failure.
In the following paragraphs, the current knowledge about epigenetic mechanisms contribut-
ing to drug resistance in melanoma is summarized.
4.2. Epigenetic alterations and targeted therapy
One of the most clinically relevant observations that point towards non-genetically regu-
lated drug resistance is the concept of drug holidays, which describes the phenomenon of 
intermittent treatment schedules or treatment interruption. This delays the emergence of 
resistance. One of the first reports describing the benefit of treatment interruption was a 
case study of a patient diagnosed with an adenocarcinoma of the lungs. After initial chemo-
therapy, the patient enrolled in a phase I study of the orally active epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitor gefitinib. After 18 month of drug response, the 
disease eventually progressed and was treated with a different combination of chemother-
apy. One year after discontinuation of the initial treatment, gefitinib re-treatment resulted 
in a significant response [86]. Similar observations were further reported for patients treated 
with BRAF or BRAF/MEK inhibitors in which re-treatment with BRAF inhibitors resulted 
in a significant response after disease progression during an earlier treatment with BRAF or 
BRAF/MEK inhibitors [87]. A multi-institutional retrospective study later on found that 43% 
of patients that received re-treatment with BRAF inhibitors after disease progression and 
treatment interruption showed a clinically significant response [88]. Studies using vemu-
rafenib-naive, primary human-patient-derived melanoma xenograft mouse models showed 
that vemurafenib resistance could be delayed by intermittent dosing schedules compared to 
continuous treatment [89].
The reversibility of drug resistance observed in clinical settings matches well with findings 
of slow cycling subpopulations that have been found to allow for reversible drug tolerance in 
vitro. One of the first reports of such a drug-tolerant subpopulation showed that a very small 
fraction of cancer cells including melanoma survives treatment with drug concentrations 100-
fold higher than the IC50 [74]. These surviving cells were found to be mainly quiescent and 
in G1 arrest, they eventually continued growth in the presence of the drug. Importantly, drug 
withdrawal re-sensitized these drug-tolerant cells and re-established the same cellular hetero-
geneity as found in the initial sensitive population. Mechanistically, the surviving drug-tol-
erant cells exerted an altered chromatin state with increased expression levels of the histone 
demethylase KDM5A (JARID1A/RBP2) and concomitantly reduced levels of H3K4me2/3. 
RNAi-mediated knockdown of KDM5A confirmed that this histone demethylase is impor-
tant for the establishment of the reversible drug-tolerant state [74]. This observation of an 
epigenetically regulated mainly G1 arrested state surviving exposure to high drug concen-
trations is similar to the previously mentioned slow cycling KDM5Bhigh subpopulation that 
is important for continuous melanoma growth [54]. KDM5Bhigh cells have been found to be 
enriched upon drug treatment and resemble a slow cycling drug-tolerant state in melanoma 
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as shRNA-mediated knockdown of KDM5B increased sensitivity to different drugs [90]. In 
accordance with the dynamic nature of KDM5A and KDM5B positive subpopulations, we 
have observed that chronic exposure to external stressors, rather than specific drug treatment, 
initiates an innate cellular response whereupon cells adopt a slow cycling, multidrug-tolerant 
phenotype [91]. Continuous exposure of melanoma cells to sub lethal BRAF inhibitor concen-
trations for 12 days initiated a cellular transformation and not the selection of a pre-existing 
subpopulation, which resulted in a slow cycling, mainly G1 arrested phenotype. These so 
called induced drug-tolerant cells (IDTCs) were unresponsive to 20-fold higher BRAF inhibi-
tor concentrations as well as multiple other drugs including the MEK inhibitor GSK1120212 
or cisplatin. As demonstrated for the KDM5Ahigh subpopulation [74], IDTCs re-gained drug 
sensitivity upon 7 days of drug withdrawal. On the molecular level IDTCs displayed elevated 
expression of drug efflux genes including ABCB5, ABCA5, ABCB8 and ABCB4, as well as 
melanoma stem cell markers NGFR, SOX10, CD44, SOX2 and SOX4, suggesting the transi-
tion into an undifferentiated state [91]. These molecular changes were accompanied by a pro-
found decrease of histone marks H3K4me3, H3K27me3 that were decreased and H3K9me3, 
which was increased. Accordingly, expression of several histone-modifying enzymes includ-
ing the H3K27-specific demethylases, KDM6A, KDM6B and the H3K4-specific demethylases, 
KDM1B, KDM5A and KDM5B was increased at the IDTC state [91]. Interestingly, a simi-
lar transition into an H3K4me3low/H3K27me3low/H3K9me3high state was triggered by hypoxia 
and nutrient starvation and IDTCs generated by these stressors exhibited tolerance to BRAF 
inhibitors or cisplatin treatment, suggesting an epigenetically regulated drug-independent 
generic stress response that allows cells to cope with difficult environmental conditions [91]. 
Similar to our proposed IDTCs, a slow cycling, reversible NGFRhigh state that displays features 
of de-differentiation has also been described, which has been shown to be susceptible to inhi-
bition of epigenetic modifiers as bromodomain inhibitors, that block recognition of acetylated 
histones, suppressed the slowly cycling NGFRhigh state [92].
Multiple studies proposed strategies to target the slow cycling drug-tolerant phenotype. 
Sharma, et al. showed that the KDM5Ahigh subpopulation that emerged after exposure to 
very high drug concentrations was susceptible to histone deacetylase (HDAC) inhibitors [74] 
because KDM5A is associated with histone decatylases during removal of histone modifica-
tion marking active transcription [93]. HDAC inhibitors induced apoptosis in this subpopu-
lation and combination of HDAC inhibitors with other drugs prevented the emergence of 
acquired resistance. Interestingly, HDAC inhibitors have to be present during the cytotoxic 
treatment as pre-treatment with histone deacetylase inhibitors followed by exposure to cyto-
toxic drugs alone was not sufficient to block acquired resistance [74]. This is important as it 
suggests that drug resistance is not mediated by a pre-existing subpopulation that carries 
intrinsic resistance mechanisms like additional mutations that can be eradicated, but by a 
dynamically regulated adaptive response that allows cancer cells to withstand unfavorable 
and toxic conditions. Roesch, et al. found that the KDM5Bhigh population enriched upon drug 
treatment in melanoma is dependent on oxidative phosphorylation as several members of the 
electron transport chain, including NADH dehydrogenase, ubiquinol cytochrome c reduc-
tase, cytochrome c oxidase and ATP synthase are highly expressed in these cells [90]. They 
further described that inhibition of the mitochondrial respiratory chain using oligomycin, 
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rotenone or phenformin blocked endogenous KDM5B expression and decreased the drug-
induced enrichment of KDM5Bhigh cells. Furthermore, combination of orally available NADH 
dehydrogenase inhibitor phenformin with BRAF inhibitor vemurafenib increased the tumor 
suppressive effects in vivo [90]. In the same year, Yuan, et al. showed AMPK-dependent syner-
gistic cytotoxicity of combining BRAF inhibitors and phenformin which also suppressed the 
emergence of a drug-resistant phenotype [94].
The IDTC phenotype described by us is characterized by elevated expression of several his-
tone-modifying enzymes showing no specific susceptibility to combinations of BRAF inhibi-
tors with HDAC inhibitors, AKT inhibitors or oligomycin [91]. In accordance with previous 
studies, knockdown of KDM5B-sensitized melanoma cells to BRAF inhibition, but the surviv-
ing cells again displayed the IDTC phenotype. Exposure of established IDTCs to different 
drugs including MEK, AKT and HDAC inhibitors showed that these compounds effectively 
suppressed their target pathways within 3 days of treatment. However, slow cycling mela-
noma cells were able to adapt to this additional stressor and re-activated the respective path-
ways within 12 days of drug exposure. In the case of HDAC inhibitors, methylation patterns 
of histone 3 lysine 4 and 9, which have been shown to be co-regulated with histone acetylation 
via transcriptional regulation of histone methyltransferases and histone demethylases [95, 96] 
were re-established to resemble the H3K4me3low/H3K9me3high pattern seen in the slow cycling 
multidrug-tolerant cells [91]. A possible explanation for the discrepancy between the discussed 
studies in regards to the different strategies to target heterogenous slow cycling populations 
could be that the KDM5Ahigh or KDM5Bhigh cells are stringently selected subtypes of the slow 
cycling phenotype whereas IDTCs are characterized by multiple epigenetic modifiers, most 
likely including multiple subtypes that contribute to the same phenomenon. The dynamic sig-
naling rewiring observed in the IDTC phenotype is reminiscent of the diverse drug resistance 
mechanisms that have been reported to emerge from slow cycling EGFR inhibitor addicted 
lung cancer cells [75], which suggests that an adaptive response as described for IDTCs in 
melanoma might be present in multiple cancer types. One key feature of all slow cycling 
drug-tolerant cell populations that emerge after 3–12 days of drug exposure is the reversibil-
ity upon drug withdrawal. However long-term exposure (90 days) of melanoma cells to BRAF 
inhibitors resulted in loss of the IDTC markers NGFR as well as KDM5B [91]. Interestingly, 
these cells displayed no multidrug resistance but maintained resistance to BRAF inhibitors 
despite drug withdrawal, suggesting the emergence of permanent resistance [91].
4.3. Epigenetic alterations and immunotherapy
Epigenetic regulation is a key mechanism for maintaining immune cell identity and differ-
entiation. For example, CD8 positive cytotoxic T lymphocytes undergo dynamic changes of 
DNA methylation and histone modification patterns following infection that are important 
for regulation and maintenance of their differentiation states [97]. Therefore, it is important 
to consider that epigenetic targeting drugs will not only affect tumor cells but also influence 
immune cells and other cells of the tumor microenvironment. Herein, the effects of epigenetic 
alterations within cancer cells, specifically melanoma, and how these changes affect the thera-
peutic effect of immunotherapy will be discussed.
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The most promising immunotherapies currently in clinical use are anti-PD-1 and PD-L1 ther-
apies [98]. Analyses of 52 immunotherapy-naïve stage III melanomas specimens in regard to 
the PD-L1 expression suggested that PD-L1 negative status is associated with worse prognosis 
and a poor immune response gene signature. PD-L1 positive melanomas showed a significant 
association with the TCGA hypomethylation cluster suggesting that upregulation of immune 
checkpoint inhibitors is found in cancer cells with altered gene expression. Another study 
showed that treatment with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine 
activates a viral defense pathway. Expression levels of these viral defense genes grouped 
different cancers including melanoma into separate categories where high expression was 
associated with the TCGA immune reactive (IMR) tumors with a good prognosis [99]. 
Melanoma patients with high levels of the viral defense signature correlated with response 
to anti-CTLA-4 for more than 6 month and combined treatment of 5-aza-2′-deoxycytidine 
and anti-CTLA4 immune checkpoint therapy in a B16-F10 mouse melanoma model enhanced 
tumor responses [99]. Another important factor for the successful immunotherapy response is 
the expression of tumor-associated antigens [100]. Along this line, it has been shown that the 
expression of high molecular weight-melanoma associated antigen (HMW-MAA) is regulated 
by DNA methylation as its expression correlates with promoter methylation. As such it is 
induced by treatment with 5-aza-2′-deoxycytidine [101].
Multiple studies reported the importance of histone modifications for the regulation of immu-
nogenic factors. For example, H3K4me3 dependent PD-L1 expression has been observed in 
pancreatic cancer [102] or H3K27me3 and DNA methylation-mediated silencing of Th1-type 
chemokines CXCL9 and CXCL10 in ovarian cancer cells [103], suggesting an important role 
for histone modifications in the regulation of immunomodulatory factors across different can-
cer types. Further evidence of epigenetically regulated PD-L1 expression is provided by stud-
ies using HDAC inhibitors in melanoma cell lines. Specifically, treatment with class I HDAC 
inhibitors resulted in increased acetylation of histone 3 in PD-L1 and PD-L2 promoter regions, 
which resulted in increased PD-L1 expression in vitro and in vivo [104].
5. Conclusion
Keeping in mind the wealth of data describing epigenetic alterations during melanoma devel-
opment and also in relation to the therapeutic response targeting or co-targeting these epigen-
etic events appears to be a very promising strategy for improving melanoma management. 
This is especially true in light of the highly heterogeneous and adaptive nature of melanoma 
which cannot be explained only by stable genetic events. While epigenetic biomarkers have 
not yet been put to clinical use, there is an overwhelming number of clinical trials utilizing 
and testing epigenetic drugs in different cancer types. These trials investigate the use of gen-
eral epigenetic inhibitors targeting histone deacetylases, bromodomain and extra-terminal 
(BET) proteins (histone acetylation binding proteins) and more specific inhibitors targeting 
DNMT1, IDH1 and IDH2 (affect TET enzyme function), EZH2, DOT1L (histone H3K79 meth-
yltransferase) or KDM1A [105].
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Additionally, epigenetic drugs are tested in combination with already established chemo-, 
targeted- and immunotherapies. Besides synergistic effects of these drugs, this approach 
could also result in prevention or reversion of drug resistance, a concept that has already been 
shown in vitro more than 15 years ago [106]. In melanoma, one clinical trial is currently inves-
tigating the combination of the BRAF/MEK inhibitors vemurafenib and cobimetinib with the 
DNA hypomethylating agent decitabine (NCT01876641). However, the main focus in the field 
appears to be the combination of epigenetic drugs, especially DNA methyltransferase and 
histone deacetylase inhibitors with immunotherapy, which is currently tested in numerous 
clinical trials [107] and the outcome of these promising approaches is highly anticipated.
While these current clinical trials hold great promise, improved understanding of detailed 
epigenetic mechanisms, identification of new key players in epigenetic remodeling and the 
subsequent development of specific inhibitors, which modulate and target epigenetics have 
the potential to shape the future of melanoma therapy.
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